PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pyxis Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.76+0.08 (+4.76%)
Close on Oct 19, 2026
- Market cap
- $112.63M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.60 (−47.62%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Pyxis Oncology, Inc. saw revenue fall 14.2% to $13.86M over fiscal 2025. Free cash flow was -$63.51M.
Revenue
$13.86M
-14.2% vs. a year earlier
Operating income
-$92.11M
TTM Q2 2026
Free cash flow
-$63.51M
FY2025
EPS, diluted
-$1.41
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $112.63M
- P/E ratio
- –
- Price to sales
- 8.13
- Price to book
- 9.84
- Dividend yield
- –
- Free cash flow yield
- -56.39%
Fundamentals
- Revenue
- $13.86M
- Net income
- -$88.73M
- EPS, diluted
- -$1.41
- Free cash flow
- -$63.51M
- Book value per share
- $0.18
- Diluted shares
- 64M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$92.11M
Net income
-$88.73M
EPS, diluted
-$1.41
Free cash flow
–
Reported periodTrailing twelve months